Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07684313 · ClinicalTrials.gov registry record

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

A clinical trial, sponsored by Edwards Lifesciences.

Not yet
Registry status
75
Enrollment target

NCT07684313: Clinical Trial study, sponsored by Edwards Lifesciences.

NCT07684313 is a clinical trial that has not yet begun recruiting, run by Edwards Lifesciences. The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07684313 has not yet begun recruiting, sponsored by Edwards Lifesciences.

NOT YET RECRUITING
Registry status
75 participants
Enrollment target

Study Summary

TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.

Primary Outcome

Mean gradient is the average flow of blood through the tricuspid valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

Interventions

  • DEVICE Edwards TRIFORMIS RESILIA heart valve

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2026-08
Est. Completion 2034-12
Edwards Lifesciences

57 total trials

What is known before NCT07684313 opens enrollment

NCT07684313 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Edwards TRIFORMIS RESILIA heart valve is the first listed.

NCT07684313 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07684313 about?

NCT07684313 is a clinical study titled "TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)". TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.

What is the current status of trial NCT07684313?

This trial is currently not yet recruiting. The enrollment target is 75 participants. The study started on 2026-08. Estimated completion is 2034-12.

What interventions are being tested in trial NCT07684313?

The interventions under investigation include: Edwards TRIFORMIS RESILIA heart valve (DEVICE).

Who is sponsoring clinical trial NCT07684313?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07684313, the US trial registry maintained by the National Library of Medicine. NCT07684313 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.